Evaluation of probable or possible dementia with lewy bodies using 123I-IMP brain perfusion SPECT, 123I-MIBG, and 99mTc-MIBI myocardial SPECT.

Department of Radiology, Fujita Health University, Toyoake, Japan.
Journal of Nuclear Medicine (Impact Factor: 5.56). 11/2007; 48(10):1641-50. DOI: 10.2967/jnumed.107.042143
Source: PubMed

ABSTRACT We evaluated the diagnostic usefulness of combination studies with a statistical mapping method in N-isopropyl-p-(123)I-iodoamphetamine ((123)I-IMP) brain perfusion SPECT, cardiac sympathetic nerve function by (123)I-metaiodobenzylguanidine ((123)I-MIBG), and myocardial function by electrocardiographically gated (99m)Tc-sestamibi ((99m)Tc-MIBI) SPECT for patients with probable or possible dementia with Lewy bodies (DLB).
Twelve patients with probable DLB (7 male, 5 female; mean age +/- SD, 72.3 +/- 5.63 y; range, 65-82 y) and 9 patients with possible DLB (3 male, 6 female; mean age +/- SD, 73.1 +/- 9.23 y; range, 59-88 y) were enrolled in this study. (123)I-IMP SPECT images were analyzed with 3-dimensional stereotactic surface projections (3D-SSP) and the severity of ischemia was classified objectively using quantitatively analytic and display software; stereotactic extraction estimation (SEE) methods were compared with a normal database. In addition, we evaluated (123)I-MIBG heart-to-mediastinum (H/M) uptake ratios. Moreover, we performed (99m)Tc-MIBI SPECT to evaluate myocardial perfusion and the left ventricular ejection fraction (LVEF) compared with a normal database.
3D-SSP images of group comparison with healthy control subjects showed significantly decreased perfusion in the parietotemporal, occipital cortex, posterior cingulated, and precuneus regions in the probable DLB group but no significant reduction in the possible DLB group. Mean H/M ratios in the probable DLB group were significantly lower than those of the possible DLB group and the control group, respectively. Ten of 12 patients (83.3%) with probable DLB and 1 of 9 patients (11.1%) with possible DLB showed severe reduction in the bilateral occipital lobe and also a low (123)I-MIBG uptake. One patient (8.3%) with probable DLB and 2 patients (22.2%) with possible DLB showed no bilateral occipital hypoperfusion but showed low (123)I-MIBG uptake. One patient (8.3%) with probable DLB and 6 patients (66.7%) with possible DLB showed no occipital hypoperfusion and normal (123)I-MIBG uptake. (99m)Tc-MIBI gated SPECT did not indicate any wall motion abnormality in any subjects.
These results suggest that combined examination of cerebral blood flow with 3D-SSP and SEE analysis, and cardiac sympathetic nerve function with (123)I-MIBG, would be a useful supporting diagnostic method in patients with DLB-particularly, in possible DLB and when cerebral blood flow does not indicate occipital hypoperfusion.

Download full-text


Available from: Yuta Manabe, Jul 07, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The sympathetic nervous system greatly influences cardiovascular physiology, and the importance of cardiac innervation abnormalitiesinthephysiopathologyof variouscardiacdiseases has been emphasised. Cardiac neurotransmission imaging with single-photon-emission computed tomography (SPECT) allows in vivo assessment of the myocardial nervous system. At present, the most commonly used SPECT tracer to assess cardiac neurotransmission is metaiodobenzylguanidine labelled with iodine-123 ( 123 I-MIBG). Cardiac 123 I-MIBG scintigraphy allows autonomic neuropathy to be detected in the early stages of diabetes mellitus. In patients with heart failure, the assessment of cardiac sympathetic activity has important prognostic implications. Targeting neuronal dysfunction with 123 I-MIBG scintigraphy in patients with heart transplantation, ischaemic heart disease, hypertension, diabetes mellitus, heart failure, drug-induced cardiotoxicity and dysautonomias can contribute to early diagnosis, prognostic stratification and appropriate treatment [1]. However, this is not all of the uses for 123 I-MIBG, as an emerging application of this tracer is being pursued for studies in movement disorders.
    European journal of nuclear medicine and molecular imaging 04/2008; 35(3):681-5. DOI:10.1007/s00259-007-0673-1 · 5.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Differential diagnosis between dementia with Lewy bodies (DLB) and other neurodegenerative diseases with cognitive impairment represents a clinical challenge. Due to the overlapping of symptoms, the clinical diagnosis can be modified during the prolonged follow-up of these diseases. The purpose of this study was to assess the ability of cardiac metaiodobenzylguanidine (MIBG) imaging for early identification of DLB. Since January 2003, all patients with neurodegenerative diseases with cognitive impairment at their first visit at the Memory Unit and clinical criteria of DLB were consecutively recruited and underwent a cardiac (123)I-MIBG study. The heart-to-mediastinum ratio (HMR) and the washout rate (WR) of cardiac MIBG uptake were obtained. Sixty-five patients were included. After a clinical follow-up of 4 years, the progress of the disease procured a definite diagnosis in 44 (68%) patients: 19 DLB, 12 Alzheimer disease (AD), and 13 other neurodegenerative diseases with cognitive impairment. HMR was significantly decreased in DLB with respect to the other neurodegenerative diseases. WR was only significantly different between DLB and AD. The HMR cut off point of 1.36 differentiated DLB from the other dementias with a sensitivity of 94% and a specificity of 96% with an accuracy of 95%. Cardiac MIBG imaging performed at the time of the first clinical diagnosis of DLB can help early clinical identification or exclusion of this disease.
    European journal of nuclear medicine and molecular imaging 06/2008; 35(9):1636-41. DOI:10.1007/s00259-008-0828-8 · 5.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Some patients with frontotemporal dementia (FTD) have concomitant extrapyramidal symptoms and psychosis and may simultaneously meet consensus criteria for FTD and for dementia with Lewy bodies (DLB). Clinicopathologic studies are helpful in understanding the underlying neurodegenerative process in such cases. To describe clinical and pathologic features of 6 patients with signs and symptoms suggestive of both a diagnosis of FTD and DLB at first clinical presentation, of which 2 patients have now undergone autopsy, and to compare them with autopsy-confirmed FTD and Lewy body disease patients. All 6 patients met published consensus criteria for a diagnosis of both FTD and DLB (5 probable and 1 possible). Clinical symptoms of FTD included personality and behavioral changes, whereas those suggestive of DLB included Parkinsonism, fluctuating cognition, parasomnia, and hallucinations. Five patients underwent single photon emission computed tomography ((99m)Tc) imaging, which showed varying degrees of frontal lobe hypoperfusion. Magnetic resonance imaging, electroencephalogram, and electromyogram were not helpful in differentiating FTD from DLB. Histologic examination of the 2 autopsy cases was consistent with a pathologic diagnosis of TDP-43 proteinopathy; specifically frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes, type 1. There were significant differences between these 6 patients and the 2 groups of autopsy confirmed FTD and Lewy body disease patients. We have identified a novel group of FTD patients with clinical features that overlap with DLB, yet seem to be different from both typical FTD and typical Lewy body disease.
    Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology 10/2008; 21(3):157-63. DOI:10.1097/WNN.0b013e3181864a09 · 1.14 Impact Factor